PMID- 15892594
OWN - NLM
STAT- MEDLINE
DCOM- 20050727
LR  - 20181113
IS  - 0012-6667 (Print)
IS  - 0012-6667 (Linking)
VI  - 65
IP  - 7
DP  - 2005
TI  - Enoxaparin: a review of its use as thromboprophylaxis in acutely ill, nonsurgical 
      patients.
PG  - 1025-36
AB  - Enoxaparin (Clexane), Lovenox) is a low molecular weight heparin (LMWH) that has 
      been widely used in the prevention of venous thromboembolism (VTE) in surgical 
      patients. More recently, with the recognition of the high incidence of VTE in 
      acutely ill medical (nonsurgical) patients, enoxaparin has been evaluated for 
      thromboprophylaxis in this patient population. Subcutaneous enoxaparin 40 mg once 
      daily has shown efficacy in the short-term thromboprophylaxis of VTE in 
      nonsurgical patients with severely restricted mobility due to acute illness in 
      well controlled clinical trials. The drug is at least similar in efficacy to 
      unfractionated heparin (UFH) and its pharmacological profile allows once-daily 
      administration, in contrast to the twice- or three-times-daily administration 
      required with UFH. The tolerability profile of enoxaparin is also similar to that 
      of UFH, except that the incidences of local haematomas and increased liver 
      enzymes are lower with enoxaparin. The optimal duration of prophylaxis in 
      nonsurgical patients is currently being evaluated and the results of extended 
      prophylaxis with enoxaparin evaluated in the EXCLAIM (EXtended CLinical 
      prophylaxis in Acutely Ill Medical patients) trial are awaited with interest. 
      Currently, short-term enoxaparin appears to provide a cost-effective treatment 
      alternative to UFH for VTE prophylaxis in nonsurgical patients.
FAU - Siddiqui, M Asif A
AU  - Siddiqui MA
AD  - Adis International Limited, Auckland, New Zealand. demail@adis.co.nz
FAU - Wagstaff, Antona J
AU  - Wagstaff AJ
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
RN  - 0 (Anticoagulants)
RN  - 0 (Antithrombins)
RN  - 0 (Enoxaparin)
SB  - IM
MH  - Acute Disease
MH  - Anticoagulants/administration & dosage/adverse 
      effects/economics/pharmacokinetics/pharmacology/*therapeutic use
MH  - Antithrombins/physiology
MH  - Blood Coagulation/drug effects
MH  - Enoxaparin/administration & dosage/adverse 
      effects/economics/pharmacokinetics/pharmacology/*therapeutic use
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Thrombosis/*prevention & control
RF  - 54
EDAT- 2005/05/17 09:00
MHDA- 2005/07/28 09:00
CRDT- 2005/05/17 09:00
PHST- 2005/05/17 09:00 [pubmed]
PHST- 2005/07/28 09:00 [medline]
PHST- 2005/05/17 09:00 [entrez]
AID - 65710 [pii]
AID - 10.2165/00003495-200565070-00009 [doi]
PST - ppublish
SO  - Drugs. 2005;65(7):1025-36. doi: 10.2165/00003495-200565070-00009.